Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603822 · ClinicalTrials.gov registry record · Phase 1
Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02603822: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02603822 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02603822, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators' overall objective with this study is to determine performance characteristics of small intestine permeability measurement using 13C mannitol and 12C (regular) mannitol.
Interventions
- DRUG Indomethacin
- DIETARY_SUPPLEMENT 12C mannitol
- DIETARY_SUPPLEMENT 13C mannitol
- DIETARY_SUPPLEMENT Lactulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603822
The ClinicalTrials.gov registry entry for NCT02603822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Indomethacin is the first listed.
NCT02603822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603822 about?
NCT02603822 is a clinical study titled "Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability". The investigators' overall objective with this study is to determine performance characteristics of small intestine permeability measurement using 13C mannitol and 12C (regular) mannitol.
What is the current status of trial NCT02603822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-08. Estimated completion is 2018-07-17.
What interventions are being tested in trial NCT02603822?
The interventions under investigation include: Indomethacin (DRUG), 12C mannitol (DIETARY_SUPPLEMENT), 13C mannitol (DIETARY_SUPPLEMENT), Lactulose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02603822?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.